Workiva Announces Julie Iskow as Chief Executive Officer
22.2.2023 00:15:00 EET | Business Wire | Press release
Workiva Inc. (NYSE: WK), the company powering transparent reporting for a better world, announced today that Julie Iskow, current President and Chief Operating Officer, has been appointed to succeed Marty Vanderploeg as Chief Executive Officer, effective April 1, 2023. Vanderploeg is stepping down as CEO, but will remain with the company in the role of Non-Executive Chair of the Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230221005356/en/
Workiva Inc. (NYSE: WK) Announces Julie Iskow as Chief Executive Officer (Photo: Business Wire)
Current Board Chair and prospective Lead Independent Director Dave Mulcahy said, “The Board is delighted to appoint Julie Iskow to Chief Executive. She is a strong, respected, and values-driven leader with an impressive and proven track record of delivering consistent high-quality performance through her relentless commitment to our customers and to our people. Julie has played an instrumental role in Workiva’s success over the last three years. She is an engineer, technologist, and strategic operator, whose innovation-first mindset has created a differentiated product offering and sustainable rigor around Workiva’s platform and solutions. The Board is confident in Julie’s ability to lead Workiva through its next stage of growth.”
Of her new role, Iskow said, “Workiva is one of the most relevant and innovative technology companies of our time. We have a transformative platform, unbridled potential, and an enduring foundation on which to build our future. I consider it a distinct privilege to succeed Marty and work with our incredibly talented team to move Workiva’s legacy forward into our next phase of growth and impact.”
Mulcahy said, “We would like to thank Marty for his steadfast leadership. During his tenure, he transformed Workiva into the leading multi-solution platform company for assured integrated business reporting, serving 5,600 customers across the globe. Marty has been an exceptional leader for Workiva, championing an employee culture of progress, product innovation, customer focus, and achieving strong shareholder value. We look forward to working with him in his expanded Board leadership role.”
“As a co-founder of Workiva, I have had the good fortune of working with a talented team for the past 15 years, five of those as CEO,” said Vanderploeg. “Now is the right time for me, and for Workiva, to make this change. Since day one of Julie’s arrival, she’s made our organization better. Julie has spent the past three years thoughtfully building and shaping our remarkable leadership team and operational strategy as we progress toward a long-term goal of $1 billion in revenue. I look forward to supporting her in my new role as Non-Executive Chair.”
About Julie Iskow
Julie Iskow joined Workiva in 2019 as EVP and Chief Operating Officer. She has extensive experience scaling enterprise SaaS companies with strong, profitable growth and has a robust background in product development and optimizing operations. Iskow was promoted to President and Chief Operating Officer in March 2022 and has been overseeing day-to-day operations with global responsibility for technology, product, sales, partners, marketing, services, and customer and partner experience. This transition allows her and the Workiva team to continue with their excellence in execution.
Before joining Workiva, Iskow served as EVP and Chief Technology Officer at Medidata Solutions, creator of cutting-edge SaaS technology and analytics solutions for life sciences. Prior to Medidata, she was the Senior Vice President of Product Development and Chief Information Officer at WageWorks, a SaaS platform for consumer directed benefits solutions. Before WageWorks, she spent over a decade in engineering and technology leadership positions, responsible for automation and robotics software used in high-tech manufacturing.
She currently serves on the board of directors of Workiva Inc. and Five9, a leading provider of cloud software for contact centers. She has a bachelor of science degree from the University of California, Berkeley and a master of science degree from the University of California, Davis.
About Workiva
Workiva Inc. (NYSE:WK) is on a mission to power transparent reporting for a better world. We build and deliver the world’s leading cloud platform for assured integrated reporting to meet stakeholder demands for action, transparency, and disclosure of financial and non-financial data. Workiva offers the only unified SaaS platform that brings customers’ financial reporting, Environmental, Social, and Governance (ESG), and Governance, Risk, and Compliance (GRC) together in a controlled, secure, audit-ready platform. Our platform simplifies the most complex reporting and disclosure challenges by streamlining processes, connecting data and teams, and ensuring consistency. Learn more at workiva.com.
Follow Workiva on LinkedIn: www.linkedin.com/company/workiva
Like Workiva on Facebook: www.facebook.com/workiva
Follow Workiva on Twitter: www.twitter.com/workiva
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230221005356/en/
Contact information
Investor Inquiries:
Mike Rost
investor@workiva.com
(515) 663-4493
Media Inquiries:
Darcie Brossart
press@workiva.com
(515) 663-4471
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
